AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback